-
公开(公告)号：US07265113B2
公开(公告)日：2007-09-04
申请号：US11035248
申请日：2005-01-13
申请人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
发明人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC分类号： C07D487/04 , A61K31/53 , A61P35/00
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US07820814B2
公开(公告)日：2010-10-26
申请号：US12399429
申请日：2009-03-06
申请人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
发明人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC分类号： C07D487/04 , A61K31/53 , A61P35/00
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US20090170853A1
公开(公告)日：2009-07-02
申请号：US12399429
申请日：2009-03-06
申请人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
发明人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC分类号： A61K31/53 , C07D487/04 , A61P35/00
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US06933386B2
公开(公告)日：2005-08-23
申请号：US10622280
申请日：2003-07-18
申请人： Rajeev S. Bhide , Junying Fan , Luca Parlanti , Stephanie Barbosa , Ligang Qian , Zhen-Wei Cai , Francis S. Gibson
发明人： Rajeev S. Bhide , Junying Fan , Luca Parlanti , Stephanie Barbosa , Ligang Qian , Zhen-Wei Cai , Francis S. Gibson
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明涉及制备下式的某些吡咯并三嗪化合物及其药学上可接受的盐的方法。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
![Pyrrolo[2,1-f][1,2,4]triazine inhibitors of kinases](/abs-image/US/2005/03/22/US06869952B2/abs.jpg.150x150.jpg)
公开(公告)号：US06869952B2
公开(公告)日：2005-03-22
申请号：US10623171
申请日：2003-07-18
申请人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa
发明人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa
IPC分类号： A61K31/53 , A61K31/5377 , A61K31/541 , A61K31/662 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/06 , A61P9/08 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/08 , A61P13/10 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/10 , A61P31/12 , A61P31/18 , A61P31/22 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P43/00 , C07D487/02 , C07D487/04 , C07F9/6561
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其用作抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US07521450B2
公开(公告)日：2009-04-21
申请号：US11832976
申请日：2007-08-02
申请人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
发明人： Rajeev S. Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC分类号： C07D487/04 , A61K31/53 , A61P19/02 , A61P35/00
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US07547711B2
公开(公告)日：2009-06-16
申请号：US11349767
申请日：2006-02-08
申请人： Robert M. Borzilleri , Rajeev S. Bhide , John S. Tokarski , Peter Zheng , Ligang Qian , Zhen-Wei Cai
发明人： Robert M. Borzilleri , Rajeev S. Bhide , John S. Tokarski , Peter Zheng , Ligang Qian , Zhen-Wei Cai
IPC分类号： A61K31/44 , C07D417/12
CPC分类号： C07D277/42 , C07D417/12 , C07D417/14
摘要： The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2，FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US07084160B2
公开(公告)日：2006-08-01
申请号：US10464139
申请日：2003-06-18
申请人： Robert M. Borzilleri , Rajeev S. Bhide , John S. Tokarski , Peter Zheng , Ligang Qian , Zhen-Wei Cai
发明人： Robert M. Borzilleri , Rajeev S. Bhide , John S. Tokarski , Peter Zheng , Ligang Qian , Zhen-Wei Cai
IPC分类号： A61K31/44 , C07D417/12
CPC分类号： C07D277/42 , C07D417/12 , C07D417/14
摘要： The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
-
公开(公告)号：US20070299075A1
公开(公告)日：2007-12-27
申请号：US11832976
申请日：2007-08-02
申请人： Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
发明人： Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC分类号： A61K31/4196 , A61P43/00 , C07D253/06
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其用作抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US20050124621A1
公开(公告)日：2005-06-09
申请号：US11035248
申请日：2005-01-13
申请人： Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
发明人： Rajeev Bhide , Zhen-Wei Cai , Ligang Qian , Stephanie Barbosa , Louis Lombardo , Jeffrey Robl
IPC分类号： A61K31/53 , A61K31/5377 , A61K31/541 , A61K31/662 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/06 , A61P9/08 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/08 , A61P13/10 , A61P13/12 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/10 , A61P31/12 , A61P31/18 , A61P31/22 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P43/00 , C07D487/02 , C07D487/04 , C07F9/6561
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , A61K2300/00
摘要： The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，从而使其成为抗癌剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.028 秒)
